Twist Bioscience Corporation $TWST Stock Purchased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lifted its holdings in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 1.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 780,419 shares of the company’s stock after purchasing an additional 13,055 shares during the period. Twist Bioscience comprises about 1.6% of Stephens Investment Management Group LLC’s portfolio, making the stock its 6th largest holding. Stephens Investment Management Group LLC owned 1.24% of Twist Bioscience worth $150,808,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TWST. Meeder Asset Management Inc. grew its holdings in shares of Twist Bioscience by 341.8% in the third quarter. Meeder Asset Management Inc. now owns 6,940 shares of the company’s stock worth $1,341,000 after purchasing an additional 5,369 shares during the last quarter. Public Sector Pension Investment Board bought a new stake in Twist Bioscience during the 3rd quarter valued at $14,107,000. Edgestream Partners L.P. bought a new stake in Twist Bioscience during the 3rd quarter valued at $5,306,000. Teachers Retirement System of The State of Kentucky purchased a new stake in Twist Bioscience during the 3rd quarter valued at $1,066,000. Finally, HighTower Advisors LLC purchased a new stake in Twist Bioscience during the 3rd quarter valued at $223,000.

Twist Bioscience Trading Up 3.9%

NASDAQ:TWST opened at $116.35 on Thursday. The company has a 50-day moving average price of $149.33 and a 200-day moving average price of $94.12. The stock has a market cap of $7.30 billion, a price-to-earnings ratio of -55.67 and a beta of 2.25. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $25.23 and a 12 month high of $219.71.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative net margin of 28.34% and a negative return on equity of 27.53%. The company had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. The business’s quarterly revenue was up 26.7% compared to the same quarter last year. Equities analysts predict that Twist Bioscience Corporation will post -1.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TWST shares. UBS Group started coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price objective on the stock. Guggenheim increased their target price on shares of Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. TD Cowen cut their target price on Twist Bioscience from $190.00 to $137.00 and set a “buy” rating on the stock in a research note on Friday, November 13th. Jefferies Financial Group set a $125.00 price target on Twist Bioscience in a report on Thursday, November 12th. Finally, Canaccord Genuity Group lowered their price target on Twist Bioscience from $205.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, November 13th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $133.92.

View Our Latest Report on TWST

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,797,004.32. Following the completion of the transaction, the insider owned 63,789 shares in the company, valued at approximately $12,048,466.32. This represents a 12.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the transaction, the senior vice president directly owned 106,632 shares of the company’s stock, valued at $20,140,652.16. This represents a 8.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is owned by company insiders.

About Twist Bioscience

(Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Further Reading

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.